References
- Baker, N. A., Sept, D., Joseph, S., Holst, M. J., & McCammon, J. A. (2001). Electrostatics of nanosystems: Application to microtubules and the ribosome. Proceedings of the National Academy of Sciences, 98(18), 10037–10041. https://doi.org/https://doi.org/10.1073/pnas.181342398
- Bhaskara, S., Knutson, S. K., Jiang, G., Chandrasekharan, M. B., Wilson, A. J., Zheng, S., Yenamandra, A., Locke, K., Yuan, J.-L., Bonine-Summers, A. R., Wells, C. E., Kaiser, J. F., Washington, M. K., Zhao, Z., Wagner, F. F., Sun, Z.-W., Xia, F., Holson, E. B., Khabele, D., & Hiebert, S. W. (2010). Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell, 18(5), 436–447. https://doi.org/https://doi.org/10.1016/j.ccr.2010.10.022
- BIOVIA, D. S. (2019). Discovery studio modeling environment; Release 2017. Dessault Systemes.
- Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature, 429(6990), 457–463. https://doi.org/https://doi.org/10.1038/nature02625
- Faehnle, C. R., & Joshua‐Tor, L. (2010). Argonaute MID domain takes centre stage. EMBO Reports, 11(8), 564–565. https://doi.org/https://doi.org/10.1038/embor.2010.110
- Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004). Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. Journal of Molecular Biology, 338(1), 17–31. https://doi.org/https://doi.org/10.1016/j.jmb.2004.02.006
- Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003). Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proceedings of the National Academy of Sciences, 100(8), 4389–4394. https://doi.org/https://doi.org/10.1073/pnas.0430973100
- Harada, T., Ohguchi, H., Grondin, Y., Kikuchi, S., Sagawa, M., Tai, Y.-T., Mazitschek, R., Hideshima, T., & Anderson, K. C. (2017). HDAC3 regulates DNMT1 expression in multiple myeloma: Therapeutic implications. Leukemia, 31(12), 2670–2677. https://doi.org/https://doi.org/10.1038/leu.2017.144
- Hassanzadeh, M., Bagherzadeh, K., & Amanlou, M. (2016). A comparative study based on docking and molecular dynamics simulations over HDAC-tubulin dual inhibitors. Journal of Molecular Graphics & Modelling, 70, 170–180. https://doi.org/https://doi.org/10.1016/j.jmgm.2016.10.007
- Hassanzadeh, M., Kasymov, R., Mahernia, S., Adib, M., Emperle, M., Dukatz, M., Bashtrykov, P., Jeltsch, A., & Amanlou, M. (2017). Discovery of novel and selective DNA methyltransferase 1 inhibitors by pharmacophore and docking-based virtual screening. ChemistrySelect, 2(27), 8383–8392. https://doi.org/https://doi.org/10.1002/slct.201701734
- Hellebrekers, D. M. E. I., Griffioen, A. W., & Engeland, M. v. (2007). Dual targeting of epigenetic therapy in cancer. Biochimica et Biophysica Acta, 1775(1), 76–91. https://doi.org/https://doi.org/10.1016/j.bbcan.2006.07.003 https://www.uniprot.org/uniprot/Q9UBN7#family_and_domains.
- Kamb, A., Wee, S., & Lengauer, C. (2007). Why is cancer drug discovery so difficult? Nature Reviews. Drug Discovery, 6(2), 115–120. https://doi.org/https://doi.org/10.1038/nrd2155
- Klein, C., Kemmel, V., Taleb, O., Aunis, D., & Maitre, M. (2009). Pharmacological doses of gamma-hydroxybutyrate (GHB) potentiate histone acetylation in the rat brain by histone deacetylase inhibition. Neuropharmacology, 57(2), 137–147. https://doi.org/https://doi.org/10.1016/j.neuropharm.2009.04.013
- Kristensen, L. S., Nielsen, H. M., & Hansen, L. L. (2009). Epigenetics and cancer treatment. European Journal of Pharmacology, 625(1–3), 131–142. https://doi.org/https://doi.org/10.1016/j.ejphar.2009.10.011
- Kumari, R., Kumar, R., Open Source Drug Discovery Consortium, & Lynn, A. (2014). g_mmpbsa-a GROMACS tool for high-throughput MM-PBSA calculations. Journal of Chemical Information and Modeling, 54(7), 1951–1962. https://doi.org/https://doi.org/10.1021/ci500020m
- Lehmann, M., Hoffmann, M. J., Koch, A., Ulrich, S. M., Schulz, W. A., & Niegisch, G. (2014). Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment. Journal of Experimental & Clinical Cancer Research: CR, 33(1), 59. https://doi.org/https://doi.org/10.1186/s13046-014-0059-8
- Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26. https://doi.org/https://doi.org/10.1016/S0169-409X(00)00129-0
- Mai, A., Massa, S., Ragno, R., Cerbara, I., Jesacher, F., Loidl, P., & Brosch, G. (2003). 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures. Journal of Medicinal Chemistry, 46(4), 512–524. https://doi.org/https://doi.org/10.1021/jm021070e
- Mai, A., & Altucci, L. (2009). Epi-drugs to fight cancer: From chemistry to cancer treatment, the road ahead. The International Journal of Biochemistry & Cell Biology, 41(1), 199–213. https://doi.org/https://doi.org/10.1016/j.biocel.2008.08.020
- Makarewicz, T., & Kaźmierkiewicz, R. (2013). Molecular dynamics simulation by GROMACS using GUI plugin for PyMOL. ACS Publications.
- Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001). Histone deacetylases and cancer: Causes and therapies. Nature Reviews. Cancer, 1(3), 194–202. https://doi.org/https://doi.org/10.1038/35106079
- Marks, P. A., Xu, W., & Namdar, M. (2017). HDAC 6 inhibitor-based methods for treating cancer. (U.S. Patent No. 9,539,272). 10 Jan 2017.
- Martin, M., Kettmann, R., & Dequiedt, F. (2007). Class IIa histone deacetylases: Regulating the regulators. Oncogene, 26(37), 5450–5467. https://doi.org/https://doi.org/10.1038/sj.onc.1210613
- Minucci, S., & Pelicci, P. G. (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature Reviews. Cancer, 6(1), 38–51. https://doi.org/https://doi.org/10.1038/nrc1779
- Moradei, O., Maroun, C. R., Paquin, I., & Vaisburg, A. (2005). Histone deacetylase inhibitors: Latest developments, trends and prospects. Current Medicinal Chemistry. Anti-Cancer Agents, 5(5), 529–560. https://doi.org/https://doi.org/10.2174/1568011054866946
- Morphy, R., Kay, C., & Rankovic, Z. (2004). From magic bullets to designed multiple ligands. Drug Discovery Today, 9(15), 641–651. https://doi.org/https://doi.org/10.1016/S1359-6446(04)03163-0
- Morphy, R., & Rankovic, Z. (2005). Designed multiple ligands. An emerging drug discovery paradigm. Journal of Medicinal Chemistry, 48(21), 6523–6543. https://doi.org/https://doi.org/10.1021/jm058225d
- Nishioka, C., Ikezoe, T., Yang, J., Udaka, K., & Yokoyama, A. (2011). Simultaneous inhibition of DNA methyltransferase and histone deacetylase induces p53-independent apoptosis via down-regulation of Mcl-1 in acute myelogenous leukemia cells. Leukemia Research, 35(7), 932–939. https://doi.org/https://doi.org/10.1016/j.leukres.2011.04.004
- Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., Fischer, M., & Witt, O. (2009). Histone deacetylase 8 in neuroblastoma tumorigenesis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 15(1), 91–99. https://doi.org/https://doi.org/10.1158/1078-0432.CCR-08-0684
- Park, S. Y., Jun, J. A., Jeong, K. J., Heo, H. J., Sohn, J. S., Lee, H. Y., Park, C. G., & Kang, J. (2011). Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncology Reports, 25(6), 1677–1681. https://doi.org/https://doi.org/10.3892/or.2011.1236
- Pilarsky, C., Wenzig, M., Specht, T., Saeger, H. D., & Grützmann, R. (2004). Identification and validation of commonly overexpressed genes in solid tumors by comparison of microarray data. Neoplasia (New York, N.Y.), 6(6), 744–750. https://doi.org/https://doi.org/10.1593/neo.04277
- Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., Hess, B., & Lindahl, E. (2013). GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics (Oxford, England), 29(7), 845–854. https://doi.org/https://doi.org/10.1093/bioinformatics/btt055
- Qian, Y., Zhang, J., Jung, Y.-S., & Chen, X. (2014). DEC1 coordinates with HDAC8 to differentially regulate TAp73 and ΔNp73 expression. PloS One, 9(1), e84015. https://doi.org/https://doi.org/10.1371/journal.pone.0084015
- Rudnitskay, A., Török, B., & Török, M. (2010). Molecular docking of enzyme inhibitors: A computational tool for structure-based drug design. Biochemistry and Molecular Biology Education, 38(4), 261–265. https://doi.org/https://doi.org/10.1002/bmb.20392
- Ruijter, A. J. M. d., Gennip, A. H. v., Caron, H. N., Kemp, S., & Kuilenburg, A. B. P. v. (2003). Histone deacetylases (HDACs): Characterization of the classical HDAC family. The Biochemical Journal, 370(Pt 3), 737–749. https://doi.org/https://doi.org/10.1042/BJ20021321
- Saini, S. K., Mangalhara, K. C., Prakasam, G., & Bamezai, R. N. K. (2017). DNA Methyltransferase1 (DNMT1) Isoform3 methylates mitochondrial genome and modulates its biology. Scientific Reports, 7(1), 1525https://doi.org/https://doi.org/10.1038/s41598-017-01743-y
- Sixto-López, Y., Bello, M., Rodríguez-Fonseca, R. A., Rosales-Hernández, M. C., Martínez-Archundia, M., Gómez-Vidal, J. A., & Correa-Basurto, J. (2017). Searching the conformational complexity and binding properties of HDAC6 through docking and molecular dynamic simulations. Journal of Biomolecular Structure & Dynamics, 35(13), 2794–2814. https://doi.org/https://doi.org/10.1080/07391102.2016.1231084
- Strahl, B. D., & Allis, C. D. (2000). The language of covalent histone modifications. Nature, 403(6765), 41–45. https://doi.org/https://doi.org/10.1038/47412
- Subramaniam, D., Thombre, R., Dhar, A., & Anant, S. (2014). DNA methyltransferases: A novel target for prevention and therapy. Frontiers in Oncology, 4, 80. https://doi.org/https://doi.org/10.3389/fonc.2014.00080
- Turner, B. M. (2002). Cellular memory and the histone code. Cell, 111(3), 285–291. https://doi.org/https://doi.org/10.1016/S0092-8674(02)01080-2
- Uciechowska, U., Schemies, J., Scharfe, M., Lawson, M., Wichapong, K., Jung, M., & Sippl, W. (2012). Binding free energy calculations and biological testing of novel thiobarbiturates as inhibitors of the human NAD + dependent histone deacetylase Sirt2. MedChemComm, 3(2), 167–173. https://doi.org/https://doi.org/10.1039/C1MD00214G
- Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., Steinkühler, C., & Di Marco, S. (2004). Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 101(42), 15064–15069. https://doi.org/https://doi.org/10.1073/pnas.0404603101
- Waltregny, D., de Leval, L., Glénisson, W., Ly Tran, S., North, B. J., Bellahcène, A., Weidle, U., Verdin, E., & Castronovo, V. (2004). Expression of histone deacetylase 8, a class I histone deacetylase, is restricted to cells showing smooth muscle differentiation in normal human tissues. American Journal of Pathology, 165(2), 553–564. https://doi.org/https://doi.org/10.1016/S0002-9440(10)63320-2
- Wang, J., Wang, W., Kollman, P. A., & Case, D. A. (2006). Automatic atom type and bond type perception in molecular mechanical calculations. Journal of Molecular Graphics and Modelling, 25(2), 247–260. https://doi.org/https://doi.org/10.1016/j.jmgm.2005.12.005
- Wilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006). Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. The Journal of Biological Chemistry, 281(19), 13548–13558. https://doi.org/https://doi.org/10.1074/jbc.M510023200
- Wolber, G., & Langer, T. (2005). LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. Journal of Chemical Information and Modeling, 45(1), 160–169. https://doi.org/https://doi.org/10.1021/ci049885e
- Yan, W., Liu, S., Xu, E., Zhang, J., Zhang, Y., Chen, X., & Chen, X. (2013). Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8. Oncogene, 32(5), 599–609. https://doi.org/https://doi.org/10.1038/onc.2012.81
- Yang, X., Ewald, E. R., Huo, Y., Tamashiro, K. L., Salvatori, R., Sawa, A., Wand, G. S., & Lee, R. S. (2012). Glucocorticoid-induced loss of DNA methylation in non-neuronal cells and potential involvement of DNMT1 in epigenetic regulation of Fkbp5. Biochemical and Biophysical Research Communications, 420(3), 570–575. https://doi.org/https://doi.org/10.1016/j.bbrc.2012.03.035
- Zhang, K., Lu, Y., Jiang, C., Liu, W., Shu, J., Chen, X., Shi, Y., Wang, E., Wang, L., Hu, Q., Dai, Y., & Xiong, B. (2017). HDAC8 functions in spindle assembly during mouse oocyte meiosis. Oncotarget, 8(12), 20092–20102. https://doi.org/https://doi.org/10.18632/oncotarget.15383
- Zou, H., Wu, Y., Navre, M., & Sang, B.-C. (2006). Characterization of the two catalytic domains in histone deacetylase 6. Biochemical and Biophysical Research Communications, 341(1), 45–50. https://doi.org/https://doi.org/10.1016/j.bbrc.2005.12.144